MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Cognitive dysfunction"

  • 2025 International Congress

    Approach into the genetics of cognitive performance in Mexican Parkinson’s Disease patients.

    A. Lázaro Figueroa, P. Reyes-Pérez, A. Morales, E. Morelos-Figaredo, C. Guerra-Galicia, I. Estrada-Bellmann, N. Gandarilla-Martínez, K. Salinas-Barboza, D. Oropeza, J. Esquivias, I. Hernández-Ruiz, G. de Anda, E. Waldo, T. Leal, M. Inca-Martinez, I. Mata, S. Alcauter, M. Rentería, A. Medina-Rivera, A. Ruiz-Contreras (CDMX, Mexico)

    Objective: To compare the allele frequencies of genetic variants associated with cognitive impairment between Parkinson's Disease (PD) patients and controls and to examine their interaction…
  • 2025 International Congress

    Decline in Motor Function and Cognitive Abilities in GBA PD Compared to Idiopathic PD (iPD)

    B. Mangal, C. Edgar, O. Siddiqui, M. Facheris, M. Hagey, D. Weintraub, T. Simuni (Chicago, USA)

    Objective: To compare disease progression events between GBA PD and iPD using the Parkinson’s Progression Markers Initiative (PPMI) database Background: GBA PD patients exhibit more…
  • 2025 International Congress

    The Role of Polygenic Background and APOE E4 in Monogenic and Idiopathic Parkinson’s Disease

    M. Kmiecik, M. Holmes, P. Fontanillas, G. Riboldi, R. Schneider, J. Shi, A. Guan, S. Tat, K. Stagaman, J. Gottesman, D. Hinds, J. Tung, S. Aslibekyan, L. Norcliffe-Kaufmann (Sunnyvale, USA)

    Objective: To assess the impact of 1) polygenic risk scores (PRS) on monogenic Parkinson’s disease (PD) risk and time to diagnosis and 2) APOE E4…
  • 2025 International Congress

    Medication Administration Burden in Lewy Body Dementia Caregivers

    W. Ayele, J. Hemm, S. Mitchell Chen, E. Stevens, A. Taylor, K. Fargo, D. Mariani, S. Seshadri, C. Bentley, T. Manak, A. Miller, C. Pensyl, C. Pierce, M. Voss, B. Ouyang, J. Chodosh, J. Fleisher (Chicago, USA)

    Objective: To evaluate medication administration burden among Lewy Body Dementia (LBD) family caregivers and associations with caregiver and care recipient characteristics. Background: Family caregivers of…
  • 2025 International Congress

    A Randomized Clinical Trial of Immersive Virtual Reality and Cognitive Rehabilitation for Mild Cognitive Impairment in Parkinson’s Disease

    A. Puig-Davi, A. Moreu-Valls, S. Martinez-Horta, G. Kulisevsky, J. Rodriguez-Antiguedad, A. Horta-Barba, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

    Objective: To investigate the efficacy of Immersive Virtual Reality (IVR) and Computerized Cognitive Training (CCT) for mild cognitive impairment in Parkinson’s disease (PD-MCI) Background: PD-MCI…
  • 2025 International Congress

    Determinants of Cognitive Progression in Parkinson’s Disease: A Machine Learning Approach

    AJ. Hernández-Medrano, A. Cervantes-Arriaga, MF. Medina-Pérez, D. Ulloa-Hernández, MF. Velasco-Delgado, GA. Martin-Mafud, AE. López-Lobato, D. Náfate-Wences, M. Rodríguez-Violante (Mexico City, Mexico)

    Objective: To identify clinical and sociodemographic factors associated with cognitive decline (CD) in PD using a Random Forests model, classifying people with PD (PwP) into…
  • 2025 International Congress

    Baseline cerebrospinal levels of p-tau and amyloid beta and striatal dopamine transporter binding predict mild cognitive impairment and dementia diagnosis in Parkinson’s disease

    L. Collins-Praino, A. Mcnamara, I. Baetu (Adelaide, Australia)

    Objective: To assess whether baseline measurements of neuroimaging and biofluid-based biomarkers predict diagnosis of mild cognitive impairment (MCI) and dementia at 5-year follow-up in early…
  • 2025 International Congress

    Variations of Self-Perceived Cognitive Changes by Ethnicity in Parkinson’s Disease Patients

    H. Lee, P. Parekh, A. Arroyo, I. Balbo, A. Fanning, R. Alcalay, J. Agin-Liebes (New York, USA)

    Objective: To study perceptions of cognitive function across ethnic groups by comparing a subjective rating with an objective assessment for patients with PD (PWP). Background:…
  • 2025 International Congress

    Tendencies of Non-Motor Symptoms and Short-Term Clinical Predictors in Patients with Parkinson’s Disease

    R. Nakagawa, M. Shiraishi, N. Takao, H. Matsumoto (Kawasaki City, Kanagawa Prefecture, Japan)

    Objective: This study retrospectively investigated whether the occurrence of non-motor symptoms and the decline in cognitive function in patients with Parkinson’s disease (PD) influence fall…
  • 2025 International Congress

    Predictors of Cognitive Impairments and Mood Disorders after Subthalamic Deep Brain Stimulation in Patients with Parkinson’s Disease

    O. Alenikova, M. Dymkovskaya, A. Bunyak, E. Mykitchuk, S. Kantsevich (Minsk, Belarus)

    Objective: We aimed to determine the predictors of cognitive decline and mood disorders after STN-DBS in PD. Background: Cognitive impairment and mood disorders are the…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 128
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley